English
Regional settings| Spread | 0.05 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 0.38 |
| Open | 0.39 |
| 1-Year Change | -88.25% |
| Day's Range | 0.38 - 0.39 |
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Its pipeline is focused on three core areas: gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies and CAR T therapies for solid tumors. Its products include MB-107 and MB-207 is Ex vivo Lentiviral Therapy for X-linked Severe Combined Immunodeficiency (XSCID). XSCID is a rare genetic immune system condition also known as bubble boy disease. Its MB-102 is a CD123 CAR T cell Program for blastic plasmacytoid dendritic cell neoplasm (BPDCN), acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
BRIEF: For the nine months ended 30 September 2021, Mustang Bio Inc revenues was not reported. Net loss increased 18% to $46.3M. Higher net loss reflects Research and development - Balan increase of 35% to $33.4M (expense), General and administrative - Balancin increase of 28% to $7.5M (expense), Stock-based Compensation in R&D increase of 41% to $1.6M (expense).
